Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2006

View Archived Issues

Snapshots: Ceftobiprole results presented at ICAAC

Studies test in vitro antibacterial activity of retapamulin

Disease control noted with PTK-787/ZK-222584 in non-small cell lung cancer

Dose-finding study of weekly ZK-EPO in refractory solid tumors completed

Phase II data show efficacy of casopitant in chemotherapy-induced nausea/vomiting

Enrollment completed in morphine study with Hylenex

Epinastine begins phase II in patients with seasonal allergic rhinitis

Additional phase III results of telavancin in cSSSI

Entry blocker peptide demonstrates activity against influenza viruses

CoDa completes Series A financing

NitroMed focuses resources on development of BiDil XR

Ariad grants license to Bellicum for Argent cell-signaling regulation technology

Immtech advances preclinical pipeline of antimicrobial drug candidates

Analysis of independent study of CellCept in myasthenia gravis

Otsuka launching Physuline in Japan

BiovaxID accepted into E.U. Drug Register for Rare Diseases

New phase I trial of inhaled formulation of ALN-RSV01

Adherex regains all rights to ADH-1

Phase III data for Fentora for breakthrough pain in chronic low back pain patients

New agents for gastrointestinal disorders described in recent GSK patents

Recent patents disclose novel agents for obesity and disorders of lipoprotein metabolism

Recent Janssen patent claims complement C1s inhibitors for autoimmune disorders

Nexium approved for treatment of Zollinger-Ellison syndrome

New indication sought for Herceptin in Europe

NDA filed for Sanctura XR in overactive bladder

Elan reports on the antihyperalgesic effects of their novel B1 receptor antagonist, ELN-441958

Preclinical activity of the novel antipsychotic RGH-188

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...